Tecartus 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
R/0034 
Renewal of the marketing authorisation. 
12/10/2023 
07/12/2023 
SmPC and 
The CAT and CHMP, having reviewed the available 
Annex II 
information on the status of the fulfilment of Specific 
Obligations and having confirmed the positive benefit risk 
balance, are of the opinion that the quality, safety and 
efficacy of this medicinal product continue to be adequately 
and sufficiently demonstrated and therefore recommends 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
PSUSA/10903
Periodic Safety Update EU Single assessment - 
14/09/2023 
15/11/2023 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/202301 
brexucabtagene autoleucel 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10903/202301. 
the renewal of the conditional MA for Tecartus, subject to 
the Specific Obligations and Conditions as laid down in 
Annex II to the opinion. 
IB/0038 
B.II.b.3.a - Change in the manufacturing process of 
03/11/2023 
n/a 
the finished or intermediate product - Minor change 
in the manufacturing process 
WS/2558/G 
This was an application for a group of variations 
05/10/2023 
n/a 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
B.I.b.1.i - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Where there is no 
monograph in the European/National Ph. for the AS, 
a change in specification from in-house to a non-
official/third country Ph. 
IB/0035 
B.I.b.z - Change in control of the AS - Other 
28/09/2023 
n/a 
variation 
WS/2389/G 
This was an application for a group of variations 
25/05/2023 
n/a 
following a worksharing procedure according to 
Page 2/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
B.I.a.2.c - Changes in the manufacturing process of 
the AS - The change refers to a [-] substance in the 
manufacture of a biological/immunological substance 
which may have a significant impact on the medicinal 
product and is not related to a protocol 
B.I.a.1.e - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
change relates to a biological AS or a starting 
material [-] used in the manufacture of a 
biological/immunological product 
WS/2426 
This was an application for a variation following a 
30/03/2023 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
PSUSA/10903
Periodic Safety Update EU Single assessment - 
09/02/2023 
n/a 
PRAC Recommendation - maintenance 
/202207 
brexucabtagene autoleucel 
N/0030 
Minor change in labelling or package leaflet not 
17/01/2023 
09/10/2023 
Labelling 
connected with the SPC (Art. 61.3 Notification) 
R/0025 
Renewal of the marketing authorisation. 
15/09/2022 
15/11/2022 
The CAT and CHMP, having reviewed the available 
Page 3/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
information on the status of the fulfilment of Specific 
Obligations and having confirmed the positive benefit risk 
balance, are of the opinion that the quality, safety and 
efficacy of this medicinal product continue to be adequately 
and sufficiently demonstrated and therefore recommends 
the renewal of the conditional MA for Tecartus, subject to 
the Specific Obligation and Conditions as laid down in 
Annex II to the opinion. 
IB/0026 
B.II.g.5.c - Implementation of changes foreseen in 
21/09/2022 
09/10/2023 
Annex II 
an approved change management protocol - For a 
biological/immunological medicinal product 
WS/2247 
This was an application for a variation following a 
15/09/2022 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.I.b.1.g - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Widening of the 
approved specs for starting mat./intermediates, 
which may have a significant effect on the quality of 
the AS and/or the FP 
II/0008/G 
This was an application for a group of variations. 
21/07/2022 
02/09/2022 
SmPC, Annex 
Please refer to Scientific Discussion ‘Product Name-H-C-
Group of variations including and extension of 
and PL 
II, Labelling 
Product Number-II-Var.No’ 
indication to include treatment of adult patients with 
relapsed or refractory (r/r) B-cell acute lymphoblastic 
leukemia (B-ALL) for Tecartus and a type IB 
variation to change the Drug Product Dose 
specification for the new indication. As a 
Page 4/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
consequence, sections 2.2, 4.1, 4.2, 4.4, 4.8, 5.1 
and 5.2 of the SmPC are updated. Annex II is 
updated to reflect the new Specific Obligations for 
the new indication. The Package Leaflet and Labelling 
are updated in accordance. Version 1.1 of the RMP 
has also been submitted. Furthermore, the PI is 
brought in line with the latest QRD template. 
B.II.d.1.z - Change in the specification parameters 
and/or limits of the finished product - Other variation 
C.I.6.a - Change(s) to therapeutic indication(s) - 
Addition of a new therapeutic indication or 
modification of an approved one 
PSUSA/10903
Periodic Safety Update EU Single assessment - 
01/09/2022 
n/a 
PRAC Recommendation - maintenance 
/202201 
brexucabtagene autoleucel 
IB/0028 
B.I.a.2.a - Changes in the manufacturing process of 
23/08/2022 
n/a 
the AS - Minor change in the manufacturing process 
of the AS 
IB/0027 
B.I.b.z - Change in control of the AS - Other 
09/08/2022 
n/a 
variation 
WS/2269 
This was an application for a variation following a 
23/06/2022 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.II.b.3.z - Change in the manufacturing process of 
the finished or intermediate product - Other variation 
Page 5/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II/0019 
Update of sections 4.8 and 5.1 of the SmPC in order 
23/06/2022 
02/09/2022 
SmPC and 
The updated 24-month follow-up analyses of efficacy were 
to update the safety and efficacy information based 
Annex II 
conducted using the modified intent to treat (mITT) 
on 24-month follow-up data from all treated patients 
in cohort 1 of the pivotal clinical study, KTE-C19-102 
(ZUMA-2);  a Phase 2, multicenter, open-label study 
evaluating the safety and efficacy of KTE-X19 in 
subjects with relapsed or refractory (r/r) mantle cell 
lymphoma (MCL). This submission is in fulfilment of 
the specific obligation (SOB 004) to confirm the long-
term efficacy and safety of Tecartus in adult patients 
with relapsed/refractory (r/r) MCL. As a consequence 
Annex II E has been updated with deletion of the 
fulfilled SOB. In addition, the MAH has taken the 
opportunity to make minor editorial changes in the 
SmPC. The RMP version 2.1 has also been submitted. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
IB/0024 
B.I.a.4.z - Change to in-process tests or limits 
25/05/2022 
n/a 
applied during the manufacture of the AS - Other 
variation 
WS/2194 
This was an application for a variation following a 
22/04/2022 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
analysis set, which consisted of 68 patients treated with 
Tecartus. In the 24-month follow up analysis, the ORR and 
CR rates in the 68 patients in the mITT analysis set were 
91% and 68% respectively. 
For more information, please refer to the Summary of 
Product Characteristics. 
Page 6/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0023 
A.3 - Administrative change - Change in name of the 
21/04/2022 
02/09/2022 
SmPC, 
AS or of an excipient 
Labelling and 
PL 
II/0016 
B.II.g.2 - Introduction of a post approval change 
24/03/2022 
n/a 
management protocol related to the finished product 
WS/2197 
This was an application for a variation following a 
24/02/2022 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.I.a.2.c - Changes in the manufacturing process of 
the AS - The change refers to a [-] substance in the 
manufacture of a biological/immunological substance 
which may have a significant impact on the medicinal 
product and is not related to a protocol 
PSUSA/10903
Periodic Safety Update EU Single assessment - 
10/02/2022 
n/a 
PRAC Recommendation - maintenance 
/202107 
brexucabtagene autoleucel 
WS/2181 
This was an application for a variation following a 
27/01/2022 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
WS/2206 
This was an application for a variation following a 
16/12/2021 
24/01/2022 
SmPC, Annex 
The product information has been amended to reflect that 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
II and PL 
in the exceptional case where tocilizumab is not available 
due to a shortage that is listed in the European Medicines 
Page 7/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Agency shortage catalogue, suitable alternative measures 
to treat CRS instead of tocilizumab should be available on-
site. 
For more information, please refer to the Summary of 
Product Characteristics. 
Update of sections 4.2 and 4.4 of the SmPC and 
Annex IID  in order to add statements for the use of 
Tecartus and Yescarta exceptionally during shortage 
of tocilizumab following the "CAT recommendation 
for the use of CAR-T cell-based therapies in EU 
during shortages of tocilizumab". The RMPs for both 
products are updated accordingly (version 1.2 for 
Tecartus and version 5.2 for Yescarta). 
The update of the RMPs for both products (version 
1.2 for Tecartus and version 5.2 for Yescarta) 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
II/0012 
B.I.a.2.c - Changes in the manufacturing process of 
16/12/2021 
n/a 
the AS - The change refers to a [-] substance in the 
manufacture of a biological/immunological substance 
which may have a significant impact on the medicinal 
product and is not related to a protocol 
R/0010 
Renewal of the marketing authorisation. 
16/09/2021 
18/11/2021 
The CAT and CHMP, having reviewed the available 
information on the status of the fulfilment of Specific 
Obligations and having confirmed the positive benefit risk 
balance, are of the opinion that the quality, safety and 
efficacy of this medicinal product continue to be adequately 
and sufficiently demonstrated and therefore recommends 
the renewal of the conditional MA for Tecartus, subject to 
the Specific Obligations and Conditions as laid down in 
Annex II to the opinion. 
Page 8/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
N/0011 
Transfer of Marketing Authorisation 
17/09/2021 
24/01/2022 
PL 
WS/2071 
This was an application for a variation following a 
16/09/2021 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.I.b.2.d - Change in test procedure for AS or 
starting material/reagent/intermediate - Substantial 
change to or replacement of a 
biological/immunological/immunochemical test 
method or a method using a biological reagent for a 
biological AS 
PSUSA/10903
Periodic Safety Update EU Single assessment - 
02/09/2021 
n/a 
PRAC Recommendation - maintenance 
/202101 
brexucabtagene autoleucel 
IB/0009 
B.I.a.2.a - Changes in the manufacturing process of 
06/07/2021 
n/a 
the AS - Minor change in the manufacturing process 
of the AS 
IB/0005/G 
This was an application for a group of variations. 
12/05/2021 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.I.a.1.k - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - New 
storage site of MCB and/or WCB 
Page 9/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0003 
B.I.a.1.z - Change in the manufacturer of AS or of a 
23/04/2021 
n/a 
starting material/reagent/intermediate for AS - Other 
variation 
II/0001 
B.II.d.2.c - Change in test procedure for the finished 
22/04/2021 
n/a 
product - Substantial change to or replacement of a 
biol/immunol/immunochemical test method or a 
method using a biol. reagent or replacement of a 
biol. reference preparation not covered by an 
approved protocol 
IB/0004 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
31/03/2021 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
IB/0002 
B.I.b.1.z - Change in the specification parameters 
09/03/2021 
n/a 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
Page 10/10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
